Capricor Gets FDA Nod for DMD Cardiomyopathy Drug Trial
Capricor Therapeutics announced the completion of a mid-cycle review meeting with the FDA for its Biologics License Application (BLA)...
Adaptive Clinical Trial Design Adaptive Trial Design Addiction Psychiatry AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Innovation Clinical Trial Operations Clinical Trial Ops Brief Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage Decentralized Clinical Trials Digital Health Technologies dual diagnosis eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
Capricor Therapeutics announced the completion of a mid-cycle review meeting with the FDA for its Biologics License Application (BLA)...
Werewolf Therapeutics presented data at IMMUNOLOGY2025 demonstrating the efficacy of WTX-921, a conditionally activated IL-10 drug, in a mouse...
Opus Genetics announced one-year results from a Phase 1/2 study of its lead gene therapy candidate, OPGx-LCA5, for patients...
UNITY Biotechnology announced 36-week results from its Phase 2b ASPIRE trial of UBX1325 for diabetic macular edema (DME). The...
Chemomab Therapeutics announced positive Phase 2 SPRING trial data for nebokitug (CM-101) in primary sclerosing cholangitis (PSC) at Digestive...
Alterity Therapeutics has received Fast Track designation from the U.S. FDA for ATH434, a treatment for Multiple System Atrophy...
Regeneration Biomedical, Inc. (RBI) announced positive interim results from its Phase 1 clinical trial of a novel Alzheimer’s diseaseAlzheimer’s...
Dianthus Therapeutics has completed enrollment in its Phase 2 MaGic trial of DNTH103 for generalized Myasthenia Gravis (gMG), exceeding...
In August 2024, the FDA rejected the New Drug Application for MDMA-assisted therapy for PTSD, sponsored by Lykos Therapeutics,...
Inquis Medical announced positive results from its AVENTUS IDE trial, evaluating the safety and efficacy of its AVENTUS Thrombectomy...